Disulfiram

Property	Information
Drug Name	Disulfiram (Antabuse)
FDA Approval	Yes (for preventing alcohol consumption)
Used for	Exploratory treatment for GBM in combination with temozolomide and potentially copper gluconate
Clinical Trial Phase	Phase I pharmacodynamics trial at Washington University, ongoing research
Clinical Trial Explanation	Not specified
Common Side Effects	At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed
OS without	Not specified
OS with	Early results suggest potential efficacy in enhancing chemotherapy response; ongoing trials
PFS without	Not specified
PFS with	Initial results indicate a need for dosage optimization to balance efficacy and side effects
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	2
Toxicity Explanation	Disulfiram shows a relatively low toxicity for treating Glioblastoma, especially when no alcohol is consumed. This means it could be a safer choice for treatment. Potential side effects like delirium and peripheral motor neuropathy were only reported at higher dosages. However, ongoing research is important to maximize therapeutic outcomes and minimize any potential side effects.

Notes: Disulfiram, a drug traditionally used to prevent alcohol consumption, shows promise in GBM treatment through mechanisms such as blocking glycoprotein pumps and inhibiting MGMT enzyme and metalloproteinase activity. It's believed to inhibit the growth of cancer stem cells, a major source of treatment failures. Its anticancer effects may be potentiated by concurrent use of copper gluconate. Current trials are investigating optimal dosing and combination strategies to maximize therapeutic outcomes.

From Ben Williams Book: Not specified

Loading comments...